Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Craig-Hallum raised the firm’s price target on CVRx (CVRX) to $22 from $20 and keeps a Buy rating on the shares. CVRx posted a modest beat in ...

William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...

Craig-Hallum raised the price target on CVRx Inc (NASDAQ:CVRX) shares to $22.00 from $20.00, maintaining a Buy rating on the company's shares. The adjustment came after CVRx reported a modest beat in ...

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on CVRx (CVRX – Research Report). The company’s ...

CVRx anticipates a 35% increase in Q4 2024 revenue and a 30% increase in FY24 revenue, with shares down 1.55% premarket.

CVRx (NASDAQ:CVRX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany ...

CVRx, Inc. (NASDAQ:CVRX), a biomedical devices company with a market capitalization of $331.2 million specializing in the treatment of heart failure and hypertension through its innovative ...